XML 69 R55.htm IDEA: XBRL DOCUMENT v3.26.1
Note 13 - Commitments and Contingencies (Details Textual)
$ in Thousands, € in Millions
1 Months Ended 3 Months Ended 10 Months Ended
Aug. 31, 2024
Aug. 30, 2024
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Mar. 31, 2025
EUR (€)
Aug. 31, 2024
USD ($)
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Dec. 31, 2023
USD ($)
Feb. 28, 2026
Dec. 31, 2025
USD ($)
Jul. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Mar. 14, 2023
USD ($)
Sep. 30, 2022
USD ($)
Mar. 31, 2020
Increlex [Member]                                
Other Commitment                     $ 2,500   $ 2,500      
Business Combination, Contingent Consideration, Liability             $ 2,318       2,259          
Business Combination, Contingent Consideration, Liability, Accreted to Interest Expense             182       241          
Payments to Acquire Inventory     $ 11,540                          
Number of Quarterly Installment Payments     8                          
Business Combination, Contingent Consideration, Liability, Current             6,817       6,926          
Business Combination, Contingent Consideration, Liability, Noncurrent             1,704       3,463          
GALZIN [Member]                                
Royalties, Percentage of Net Sales,                         10.00%      
Indemnification Rights and Agreements [Member]                                
Other Commitment             0       0          
Lukare [Member] | Obligation Based on First Commercial Sale of Product [Member]                                
Other Commitment                             $ 250  
Lukare [Member] | Obligation Based on No Generic Competitors Launching in 48 Months [Member]                                
Other Commitment                             $ 500  
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on First Commercial Sale of Product [Member]                                
Royalties, Percentage of Net Sales,                           17.00%    
Other Commitment                           $ 250    
Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on Acceptance of FDA of NDA for product [Member]                                
Royalties, Percentage of Net Sales,                           12.50%    
Selenix [Member] | DS-200 [Member]                                
Revenue, Additional Based on Event and Sales-based Milestones Achievements           $ 1,500                    
Commitment, Allocation of Profits, Percentage 45.00% 50.00%       45.00%                    
Selenix [Member] | Maximum [Member] | DS-200 [Member]                                
Revenue, Additional Based on Event and Sales-based Milestones Achievements               $ 5,000                
AMMTeK [Member] | Amglidia [Member]                                
Royalties, Percentage of Net Sales,                       14.00%        
AMMTeK [Member] | Receipt of FDA Minutes [Member] | Amglidia [Member]                                
Other Commitment                       $ 500        
AMMTeK [Member] | NDA Acceptance for Review by FDA [Member] | Amglidia [Member]                                
Other Commitment                       550        
AMMTeK [Member] | NDA Approval by the FDA and First Commercial Sale [Member] | Amglidia [Member]                                
Other Commitment                       $ 1,300        
Esteve [Member] | Increlex [Member]                                
Accounts Receivable, after Allowance for Credit Loss       $ 4,327       4,327                
Esteve [Member] | Increlex [Member]                                
Proceeds From Up-front Payment | €         € 4                      
License Agreement, Purchase Price of Option to Acquire | €         € 6                      
Revenues       1,786                        
Contract with Customer, Liability       $ 2,541       $ 2,541     266          
Contract with Customer, Liability, Current             457       $ 1,817          
Contract with Customer, Liability, Noncurrent             1,762                  
Contract with Customer, Liability, Revenue Recognized             $ 158                  
Pierre Fabre [Member] | Hemangeol [Member]                                
Royalties, Percentage of Net Sales,                   8.00%            
Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] | Diurnal Limited [Member] | Maximum [Member]                                
Aggregate Value of Licensing Milestone Included in Research and Development Expense                 $ 44,000              
Royalties, Percentage of Net Sales,                               17.00%
Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] | Diurnal Limited [Member] | Minimum [Member]                                
Royalties, Percentage of Net Sales,                               11.00%